Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients

(2012) Veronika Buxhofer-Ausch et al.   AMERICAN JOURNAL OF HEMATOLOGY

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

(2012) P. J. Campbell et al.   BLOOD

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients

(2011) A. Carobbio et al.   BLOOD

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms

(2011) L. Boiocchi et al.   JOURNAL OF CLINICAL PATHOLOGY

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

(2011) G Finazzi et al.   LEUKEMIA

Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia

(2011) Luigi Gugliotta et al.   LEUKEMIA RESEARCH

Pulsatile tinnitus as a first symptom of essential thrombocythemia

(2010) Haruka Okazaki et al.   AMERICAN JOURNAL OF OTOLARYNGOLOGY

Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

(2009) T. Barbui et al.   BLOOD

Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation

(2009) Petro E. Petrides et al.   CLINICAL THERAPEUTICS

JAK2V617F allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis

(2009) Kais Hussein et al.   EXPERIMENTAL HEMATOLOGY

Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy

(2009) Peter J. Campbell et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

(2008) F. Passamonti et al.   HAEMATOLOGICA

Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia

(2008) Alessandra Carobbio et al.   JOURNAL OF CLINICAL ONCOLOGY